Search Results
Search for other papers by Alicia Romano in
Google Scholar
PubMed
Search for other papers by Juan Pablo Kaski in
Google Scholar
PubMed
Search for other papers by Jovanna Dahlgren in
Google Scholar
PubMed
Search for other papers by Nicky Kelepouris in
Google Scholar
PubMed
Search for other papers by Alberto Pietropoli in
Google Scholar
PubMed
Search for other papers by Tilman R Rohrer in
Google Scholar
PubMed
Search for other papers by Michel Polak in
Google Scholar
PubMed
weight SDS were calculated using age- and gender-specific national references. GH, growth hormone; IGF1, insulin-like growth factor I; SDS, standard deviation score. The most common concomitant medications were CNS stimulants (12
Search for other papers by Jose M Garcia in
Google Scholar
PubMed
Search for other papers by Beverly M K Biller in
Google Scholar
PubMed
Search for other papers by Márta Korbonits in
Google Scholar
PubMed
Search for other papers by Vera Popovic in
Google Scholar
PubMed
Search for other papers by Anton Luger in
Google Scholar
PubMed
Search for other papers by Christian J Strasburger in
Google Scholar
PubMed
Search for other papers by Philippe Chanson in
Google Scholar
PubMed
Search for other papers by Ronald Swerdloff in
Google Scholar
PubMed
Search for other papers by Christina Wang in
Google Scholar
PubMed
Search for other papers by Rosa Rosanna Fleming in
Google Scholar
PubMed
Search for other papers by Fredric Cohen in
Google Scholar
PubMed
Search for other papers by Nicola Ammer in
Google Scholar
PubMed
Search for other papers by Gilbert Mueller in
Google Scholar
PubMed
Search for other papers by Nicky Kelepouris in
Google Scholar
PubMed
Search for other papers by Frank Strobl in
Google Scholar
PubMed
Search for other papers by Vlady Ostrow in
Google Scholar
PubMed
Search for other papers by Kevin C J Yuen in
Google Scholar
PubMed
on diagnosis and disease progression ( 17 ). Thus, except in patients with panhypopituitarism and low insulin-like growth factor I (IGF-I) levels, the diagnosis of AGHD often requires confirmation using a provocative GH stimulation test (GHST) ( 18
Search for other papers by Jin Kyu Oh in
Google Scholar
PubMed
Search for other papers by Young Jae Im in
Google Scholar
PubMed
Search for other papers by Kwanjin Park in
Google Scholar
PubMed
Search for other papers by Jae-Seung Paick in
Google Scholar
PubMed
underlying molecular mechanisms have not been described, the GH–insulin-like growth factor 1 (IGF1) axis is a proactive mediator of the actions of testosterone and its potent derivative dihydrotestosterone. Accordingly, stimulation of IGF1 signalling
Department of Emergency Medicine, Landspitali – The National University Hospital of Iceland, Reykjavik, Iceland
Search for other papers by Lára Ósk Eggertsdóttir Claessen in
Google Scholar
PubMed
Search for other papers by Hafrún Kristjánsdóttir in
Google Scholar
PubMed
Department of Psychology, School of Social Sciences, Reykjavik University, Reykjavik, Iceland
Search for other papers by María Kristín Jónsdóttir in
Google Scholar
PubMed
School of Engineering and Natural Sciences, University of Iceland, Reykjavik, Iceland
Search for other papers by Sigrún Helga Lund in
Google Scholar
PubMed
Search for other papers by Ingunn Unnsteinsdóttir Kristensen in
Google Scholar
PubMed
Department of Medicine, Landspitali – The National University Hospital of Iceland, Reykjavik, Iceland
Search for other papers by Helga Ágústa Sigurjónsdóttir in
Google Scholar
PubMed
expensive, a biochemical marker for GHD screening would be beneficial. Serum insulin-like growth factor 1 (s-IGF1) has been proposed as a screening tool for GHD as low s-IGF1 may indicate GHD. However, its use remains debatable as s-IGF1 within normal range
Department of Nutrition, School of Public Health, Sun Yat-Sen University, Guangzhou, People’s Republic of China
Search for other papers by Xu Chen in
Google Scholar
PubMed
Search for other papers by Yi Tang in
Google Scholar
PubMed
Search for other papers by Shen Chen in
Google Scholar
PubMed
Guangdong Provincial Key Laboratory of Food, Nutrition and Health, Guangzhou, People’s Republic of China
Search for other papers by Wenhua Ling in
Google Scholar
PubMed
Guangdong Provincial Key Laboratory of Food, Nutrition and Health, Guangzhou, People’s Republic of China
Search for other papers by Qing Wang in
Google Scholar
PubMed
.11.007 ) 19 Assefa B Mahmoud AM Pfeiffer AFH Birkenfeld AL Spranger J Arafat AM . Insulin-like growth factor (IGF) binding Protein-2, independently of IGF-1, induces GLUT-4 translocation and glucose uptake in 3T3-L1 adipocytes . Oxidative
Search for other papers by Cecilia Follin in
Google Scholar
PubMed
Search for other papers by Sven Karlsson in
Google Scholar
PubMed
diabetes and hypertension ( 3 , 4 ). The aims of treatment for acromegaly are to control/reduce tumour size, normalise GH and insulin-like growth factor 1 (IGF-1) levels and to improve comorbidities. Current treatments consist of surgery, medical therapy
Search for other papers by Adrian F Daly in
Google Scholar
PubMed
Search for other papers by Liliya Rostomyan in
Google Scholar
PubMed
Search for other papers by Daniela Betea in
Google Scholar
PubMed
Search for other papers by Jean-François Bonneville in
Google Scholar
PubMed
Department of Pathological Cytology and Anatomy, Foch Hospital, Paris, France
Search for other papers by Chiara Villa in
Google Scholar
PubMed
Search for other papers by Natalia S Pellegata in
Google Scholar
PubMed
Search for other papers by Beatrice Waser in
Google Scholar
PubMed
Search for other papers by Jean-Claude Reubi in
Google Scholar
PubMed
Search for other papers by Catherine Waeber Stephan in
Google Scholar
PubMed
Search for other papers by Emanuel Christ in
Google Scholar
PubMed
Search for other papers by Albert Beckers in
Google Scholar
PubMed
Introduction Acromegaly is a rare, classical endocrine disorder that is due to chronic excess secretion of growth hormone (GH) and insulin-like growth factor 1 (IGF-1) that has a prevalence of 1 in 8000–14,000 of the population ( 1 , 2 , 3
Search for other papers by Karim Gariani in
Google Scholar
PubMed
Diabetes Center, Faculty of Medicine, University of Geneva, Geneva, Switzerland
Search for other papers by François R Jornayvaz in
Google Scholar
PubMed
insulin-like growth factor 1 (IGF-1), angiotensinogen, thrombopoetin and hepcidin. More recently, numerous hepatokines have been described ( 54 ). Among them, the liver produces Fibroblast Growth Factor 21 (FGF21), a hormone also produced by the white
Leeds Institute for Cardiovascular and Metabolic Medicine (LICAMM), University of Leeds, Leeds, UK
Search for other papers by Nikolaos Kyriakakis in
Google Scholar
PubMed
Search for other papers by Marilena Giannoudi in
Google Scholar
PubMed
Search for other papers by Satish S Kumar in
Google Scholar
PubMed
Leeds Institute for Cardiovascular and Metabolic Medicine (LICAMM), University of Leeds, Leeds, UK
Search for other papers by Khyatisha Seejore in
Google Scholar
PubMed
Search for other papers by Georgios K Dimitriadis in
Google Scholar
PubMed
Search for other papers by Harpal Randeva in
Google Scholar
PubMed
Leeds Institute of Medical Research, University of Leeds, UK
Search for other papers by Adam Glaser in
Google Scholar
PubMed
Search for other papers by Michelle Kwok-Williams in
Google Scholar
PubMed
Search for other papers by Georgina Gerrard in
Google Scholar
PubMed
Search for other papers by Carmel Loughrey in
Google Scholar
PubMed
Search for other papers by Ahmed Al-Qaissi in
Google Scholar
PubMed
Search for other papers by Ramzi Ajjan in
Google Scholar
PubMed
Search for other papers by Julie Lynch in
Google Scholar
PubMed
Leeds Institute for Cardiovascular and Metabolic Medicine (LICAMM), University of Leeds, Leeds, UK
Search for other papers by Robert D Murray in
Google Scholar
PubMed
insulin tolerance test (ITT) or the glucagon stimulation test, where the ITT was contraindicated, was used to assess the integrity of the growth hormone (GH) and hypothalamic–pituitary–adrenal axes. Insulin-like growth factor 1 (IGF1) and thyroid function
Search for other papers by Marilena Nakaguma in
Google Scholar
PubMed
Search for other papers by Fernanda A Correa in
Google Scholar
PubMed
Search for other papers by Lucas S Santana in
Google Scholar
PubMed
Search for other papers by Anna F F Benedetti in
Google Scholar
PubMed
Search for other papers by Ricardo V Perez in
Google Scholar
PubMed
Search for other papers by Martha K P Huayllas in
Google Scholar
PubMed
Search for other papers by Mirta B Miras in
Google Scholar
PubMed
Search for other papers by Mariana F A Funari in
Google Scholar
PubMed
Search for other papers by Antonio M Lerario in
Google Scholar
PubMed
Search for other papers by Berenice B Mendonca in
Google Scholar
PubMed
Search for other papers by Luciani R S Carvalho in
Google Scholar
PubMed
Search for other papers by Alexander A L Jorge in
Google Scholar
PubMed
Search for other papers by Ivo J P Arnhold in
Google Scholar
PubMed
-visualized posterior pituitary; TPP, topic posterior pituitary lobe. Serum levels of TSH, GH, LH, FSH, PRL, cortisol, dehydroepiandrosterone sulphate, total thyroxine, free thyroxine, insulin-like growth factor 1 (IGF-1), oestradiol or testosterone levels